EC
Elmind Capital Portfolio holdings
AUM
$339M
This Fund
S&P 500
1 Year Est. Return
–
AUM
$339M
AUM Growth
–
Holding
34
Top Buys
| 1 | +$32.9M | |
| 2 | +$32.4M | |
| 3 | +$23.5M | |
| 4 |
Celldex Therapeutics
CLDX
|
+$22.8M |
| 5 |
CG Oncology
CGON
|
+$20.4M |
Top Sells
No sells this quarter
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
UroGen Pharma
URGN
$968M
| $2.34M | 0.69% |
+100,000
|
|
||
27
Immunocore
IMCR
$1.63B
| $2.02M | 0.6% |
+58,248
|
|
||
28
Design Therapeutics
DSGN
$625M
| $1.95M | 0.58% |
+207,900
|
|
||
29
enGene Holdings
ENGN
$677M
| $1.9M | 0.56% |
+210,000
|
|
||
30
Alector
ALEC
$261M
| $1.4M | 0.41% |
+900,000
|
|
||
31
Amylyx Pharmaceuticals
AMLX
$1.58B
| $1.35M | 0.4% |
+112,000
|
|
||
32
Apellis Pharmaceuticals
APLS
$2.71B
| $1.26M | 0.37% |
+50,000
|
|
||
33
Supernus Pharmaceuticals
SUPN
$3.23B
| $994K | 0.29% |
+20,000
|
|
||
34
Edgewise Therapeutics
EWTX
$3.19B
| $744K | 0.22% |
+30,000
|
|